Find
News Releases
= add release to Briefcase
| All Releases | |||
|---|---|---|---|
 |
NUCYNTATM™(tapentadol) CII Immediate Release Tablets Now Available for Relief of Moderate to Severe Acute Pain Jun 23, 2009 |
16.3 KB |
|
|
Raritan, NJ - June 23, 2009 - Patients suffering from acute pain and healthcare professionals who treat pain have a new treatment option: NUCYNTA™ (tapentadol) CII immediate release tablets. This new medication for the relief of moderate to severe acute pain in patients 18 years of age or older is now available by prescription on... |
|||
|
Johnson & Johnson Announces Regulatory Clearance for Its Planned Acquisition of Cougar Biotechnology Jun 17, 2009 |
9.5 KB |
|
|
NEW BRUNSWICK, N.J., June 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act with respect to its previously announced planned acquisition of Cougar Biotech... |
|||
|
Unique Collaboration Between TB Alliance and Tibotec to Accelerate Tuberculosis Drug Development Jun 17, 2009 |
13.6 KB |
|
|
[Seattle, WA, June 17, 2009] - A new landmark collaboration between the Global Alliance for TB Drug Development (TB Alliance), a not-for-profit, product development partnership, and Tibotec, a global pharmaceutical company, has been announced today at the Pacific Health Summit in response to the urgent need to accelerate the dis... |
|||
|
Biosense Webster to Support Landmark Clinical Trial of Atrial Fibrillation Jun 12, 2009 |
22.4 KB |
|
|
DIAMOND BAR, Calif., Jun 12, 2009 (BUSINESS WIRE) -- Biosense Webster, Inc., a leader in the diagnosis and treatment of cardiac arrhythmias, will be part of a public/private collaboration to fund a global clinical trial to compare catheter ablation to medical therapy in treating atrial fibrillation. AFib, as... |
|||
|
New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients Jun 9, 2009 |
20.5 KB |
|
|
COPENHAGEN, June 9, 2009 /PRNewswire via COMTEX News Network/ -- A new analysis demonstrated that a greater proportion of patients with moderately to severely active rheumatoid arthritis (RA) who had prior treatment with anti-tumor necrosis factor (TNF)-alpha agents and received subcutaneous injections of SIMPONI(TM) (golimumab) once every four wee... |
|||
|
Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis Jun 9, 2009 |
22.6 KB |
|
|
COPENHAGEN, June 9, 2009 /PRNewswire via COMTEX News Network/ -- Findings from open-labeled, uncontrolled extensions of two randomized, placebo-controlled Phase 3 studies showed that subcutaneous (SC) injections of SIMPONI(TM) (golimumab) 50 mg or 100 mg every four weeks provided persistent improvements in the signs and symptoms in patients with ps... |
|||
|
Johnson & Johnson Begins Tender Offer to Acquire Cougar Biotechnology Jun 5, 2009 |
9.8 KB |
|
|
NEW BRUNSWICK, N.J., June 5, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ), through a new wholly-owned subsidiary, Kite Merger Sub, Inc., today will commence a cash tender offer to purchase all outstanding shares of common stock of Cougar Biotechnology, Inc. (Nasdaq: CGRB). Johnson & Johnson reported on May 2... |
|||
|
Johnson & Johnson Highlights Pharmaceutical Growth Strategies and Robust Pipeline to Address Unmet Medical Needs Jun 4, 2009 |
14.7 KB |
|
|
NEW BRUNSWICK, N.J., June 4, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) will be reviewing the growth strategies and pipeline for its Pharmaceutical business at a meeting with the investment community today. Senior leaders from the company's pharmaceutical segment will outline how continued expansion of its... |
|||
|
Data on Investigational Drug TMC207 for Treatment of MDR-Tuberculosis, Published in New England Journal of Medicine Jun 3, 2009 |
11.2 KB |
|
|
[Mechelen Belgium, June 3, 2009] -Interim results from an ongoing phase 2, randomized, placebo-controlled trial of the investigational drug TMC207 for the treatment of multidrug-resistant tuberculosis (MDR-TB) were published in the New England Journal of Medicine today. TMC207 is being developed by Tibotec BVBA. The data show that the add... |
|||
|
New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease Jun 2, 2009 |
16.7 KB |
|
|
CHICAGO, June 2, 2009 /PRNewswire via COMTEX News Network/ -- New long-term findings from the Phase 3b study of patients with moderately to severely active Crohn's disease having inadequate response to conventional therapies, but naive to immunomodulators and biologic therapy, were presented at Digestive Disease Week today. Data from the SONIC stu... |
|||
|
FDA Advisory Panel Recommends Approval of the SEDASYS® System May 28, 2009 |
8.2 KB |
|
|
CINCINNATI, May 28, 2009 - Ethicon Endo-Surgery today announced that the Anesthesiology and Respiratory Therapy Devices Advisory Committee of the U.S. Food and Drug Administration (FDA) voted in favor of approval of the SEDASYS® System for use by physician/nurse teams to administer minimal-to-moderate propofol sedation during screening and diagn... |
|||
|
Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting May 28, 2009 |
21.6 KB |
|
|
HORSHAM, Pa., May 28, 2009 /PRNewswire via COMTEX News Network/ -- Centocor Ortho Biotech Products, L.P. today announced that data related to several compounds will be presented at the 45th American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fla., from May 29 to June 2, 2009. The studies were sponsored by Centocor Ortho Biotech... |
|||
|
FDA Issues Complete Response Letter for Rivaroxaban May 28, 2009 |
7.6 KB |
|
|
Raritan, NJ (May 28, 2009)-Ortho-McNeil announced today that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the new drug application (NDA) for rivaroxaban, an oral, once-daily anticoagulant. The NDA, filed in July 2008 by Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&... |
|||
|
Johnson & Johnson Files Arbitration Demand Against Schering-Plough to Resolve Dispute Over Agreements for REMICADE(R) and SIMPONI(TM) May 27, 2009 |
6.2 KB |
|
|
NEW BRUNSWICK, N.J., May 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- In an arbitration demand filed today with the American Arbitration Association, Johnson & Johnson (NYSE: JNJ) has requested a ruling that the agreement and plan of merger between Merck & Co., Inc., and Schering-Plough Corporation constitutes a change of control that... |
|||
|
Johnson & Johnson to Host Pharmaceutical Business Review May 27, 2009 |
5.8 KB |
|
|
NEW BRUNSWICK, N.J., May 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) will host a review of its Pharmaceutical business for the investment community, beginning at 8:30 a.m. (Eastern Time) on Thursday, June 4th. Sheri McCoy, Worldwide Chairman, Pharmaceuticals Group for Johnson & Johnson, will host the me... |
|||
|
FDA Extends Review Timeline for STELARA(TM) (ustekinumab) Biologic License Application by Three Months May 26, 2009 |
9.9 KB |
|
|
HORSHAM, Pa., May 26, 2009 /PRNewswire via COMTEX News Network/ -- Centocor Ortho Biotech Inc. announced today that the U.S. Food and Drug Administration (FDA) has extended by three months the review timeline for the Biologic License Application (BLA) for STELARA(TM) (ustekinumab) to provide time for a full review of an amendment to the pending app... |
|||
|
New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal May 26, 2009 |
16.2 KB |
|
|
Raritan, NJ - May 26, 2009 - It is estimated that up to 30 percent of all people who have surgery experience gastrointestinal side effects, such as nausea and vomiting. The use of opioid pain medicines during and after surgery is a leading risk factor for experiencing these side effects. Nausea and vomiting are uncomfortable and bothersome and c... |
|||
|
Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc. May 21, 2009 |
12.2 KB |
|
|
NEW BRUNSWICK, N.J., and LOS ANGELES, May 21, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) and Cougar Biotechnology, Inc. (Nasdaq: CGRB), a development stage biopharmaceutical company with a specific focus on oncology, today announced a definitive agreement whereby Cougar Biotechnology will be acquired for ap... |
|||
|
RISPERDAL® CONSTA® (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder May 19, 2009 |
19.5 KB |
|
|
SAN FRANCISCO, May 19 /PRNewswire/ -- New data demonstrate that maintenance therapy with RISPERDAL® CONSTA® (risperidone) Long-Acting Treatment (RLAT) significantly delayed the time to relapse compared to placebo in patients with Bipolar I Disorder. Results of the study were pre... |
|||
|
New Data Demonstrate RISPERDAL® CONSTA® (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia May 19, 2009 |
69.0 KB |
|
|
SAN FRANCISCO, May 19, 2009 - Schizophrenia is one of the most disabling diseases1, and frequent relapses and rehospitalization as a result of the disease place enormous burdens on patients, caregivers and society2. According to two new studies, the use of RISPERDAL® CONSTA® (risperidon... |
|||
= add release to Briefcase
